FDA Approved: IDHIFA — Supplemental Application (Celgene Corporation)

View source ↗

Summary

The FDA lists a supplemental labeling application for IDHIFA (enasidenib) by Celgene Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

SUPPL AP for IDHIFA (ENASIDENIB MESYLATE)